Comparative results using different disease-free survival definitions
| Definition of disease-free survival | Letrozole, n = 2,582 | Placebo, n = 2,586 | |
|---|---|---|---|
| Protocol definition (first event of locoregional recurrence, distant relapse, or CLBC) | 92 (3.6%) | 155 (6.0%) | |
| Hazard ratio (95% CI), P | 0.58 (0.45-0.76), 0.00003 | ||
| First event of locoregional recurrence or distant relapse excluding CLBC | 75 (2.9%) | 127 (4.9%) | |
| Hazard ratio (95% CI), P | 0.58 (0.44-0.77), 0.00015 | ||
| First event of locoregional recurrence, distant relapse, invasive CLBC (excluding DCIS/DCIS) | 89 (3.5%) | 146 (5.7%) | |
| Hazard ratio (95% CI), P | 0.60 (0.46-0.78), 0.00013 | ||
| First event of locoregional recurrence, distant relapse, or any second malignancy (including CLBC) | 142 (5.5%) | 198 (7.7%) | |
| Hazard ratio (95% CI), P | 0.71 (0.57-0.88), 0.00155 | ||
| First event of locoregional recurrence, distant relapse, or death from any cause | 122 (4.7%) | 193 (7.5%) | |
| Hazard ratio (95% CI), P | 0.62 (0.49-0.78), 0.00003 | ||
| First event of locoregional recurrence, distant relapse, any second malignancy, or death from any cause | 161 (6.2%) | 224 (8.7%) | |
| Hazard ratio (95% CI), P | 0.71 (0.58-0.87), 0.00080 | ||
NOTE: CLBC, contralateral breast cancer; DCIS, ductal carcinoma in situ; LCIS, lobular carcinoma in situ. Analyses stratified for receptor status, nodal status, and adjuvant chemotherapy are summarized.